Navigation Links
Recent Publication Supports the Cost Effectiveness of NIPT for All Pregnant Women, Regardless of Prior Risk
Date:8/10/2015

SAN CARLOS, Calif., Aug. 10, 2015 /PRNewswire/ -- Natera, Inc., (Nasdaq: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced new data that supports the use of non-invasive prenatal testing (NIPT) as a first line screening for chromosomal aneuploidies and related conditions.

Peter Benn, DSc., Professor of Genetics at the UCONN Health Center, initiated a comprehensive economic analysis of NIPT and alternative methods, one of the first studies to incorporate U.S. based clinical and cost models in a general patient population. Dr. Benn concluded, "Universal application of NIPT would increase fetal aneuploidy detection rates and can be economically justified. Replacing conventional screening with NIPT would reduce healthcare costs if it can be provided for $744 or less in the general patient population."  Dr. Benn's study, An Economic Analysis of Cell-Free DNA Non Invasive Prenatal Testing in the US General Pregnancy Population will be published in the August issue of PLOS ONE.

Two additional recently released peer-reviewed articles support Dr. Benn's conclusion that NIPT can be a cost effective screening option for all women, regardless of age or risk.

  • Walker, et al. found "Universal NIPT remained less costly than conventional MSS [maternal serum screening] so long as the cost of NIPT was below $619," in A Cost-Effectiveness Analysis of First Trimester Non-Invasive Prenatal Screening for Fetal Trisomies in the United States.2
  • Fairbrother et al., reported: "As NIPT identifies more fetal trisomies than FTS [first trimester screen], a NIPT unit cost of $665 allows a cost per trisomy case identified to be equivalent to that of FTS," in Prenatal Screening for Fetal Aneuploidies with Cell-free DNA in the General Pregnancy Population: A Cost-effectiveness Analysis.3

This data complements the September, 2015 American College of Obstetricians and Gynecologists (ACOG) and Society for Maternal Fetal Medicine (SMFM) Committee Opinion, Cell-free DNA Screening for Fetal Aneuploidy: "Any patient may choose cell-free DNA analysis, regardless of their risk status… The patient should understand the limitations and benefits of this screening paradigm in the context of alternative screening and diagnostic options."

"The body of clinical and economic data supporting NIPT is significant," said Steve Chapman, Senior Vice President and head of Natera's health policy initiatives.  "We applaud our leading society's opinion allowing women to choose cell-free DNA analysis, regardless of their risk status."

About Natera

Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its cloud-based Constellation™ software system. Tests include the Spectrum™ pre-implantation genetic test for embryo selection during IVF; the Anora™ miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon™ carrier screen to detect inherited mutations; and the Panorama™ non-invasive prenatal test (NIPT) to screen for common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer. These tests have not been cleared or approved by the U.S. Food and Drug Administration.

Contacts
GOLD PR for Natera
Jill Edgeworth, 847-778-1538
jedgeworth@goldpr.com

Natera, Inc.
Michael Hromadik, 858-442-2215
mhromadik@natera.com

1 Benn P, Curnow KJ, Chapman S, et al. (2015) An Economic Analysis of Cell-Free DNA Non-Invasive Prenatal Testing in the US General Pregnancy Population. PLoS ONE 10(7): e0132313. doi:10.1371/journal.pone.0132313

2 Walker BS, Nelson RE, Jackson BR, et al. (2015) A Cost-Effectiveness Analysis of First Trimester Non-Invasive Prenatal Screening for Fetal Trisomies in the United States. PLoS ONE 10(7): e0131402. doi:10.1371/journal.pone.0131402

3 Fairbrother G, Burigo J, Sharon T, et al. (2015) Prenatal screening for fetal aneuploidies with cell-free DNA in the general pregnancy population: a cost-effectiveness analysis. Journal of Maternal-Fetal & Neonatal Medicine.

Logo - http://photos.prnewswire.com/prnh/20150403/196532LOGO

 


'/>"/>
SOURCE Natera, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. Biotech Briefing: FDA Events & Recent Clinical Trials Fuel Therapeutic Advancements That Continue to Drive the Pharma & Biotech Sectors
2. Luzi Smart Lamp Recently Launched Indiegogo Campaign
3. Assessments of Leading Microbiology Market Players 2015 - Profiles of Major Suppliers and Recent Market Entrants
4. Accutest Recently Completed its 22nd Successful FDA Inspection
5. Soligenix Announces Recent Accomplishments and Year-End 2014 Financial Results
6. Distinct LLC, the marketer of Probiotic Action, responds to recent physician review of probiotics for acne a natural acne treatments
7. Marked Increase in Ebola Gene Replikin Count in 2012 & 2013 Predicted Current Ebola Outbreak; Does Recent Sharp Drop in Replikin Count Signal Early End for the Current Ebola Outbreak?
8. Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions
9. Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent
10. Dr. Ross Rich of Cave Creek Equine Recently Presented the Outcome of 42 Horses with Stifle Injuries Treated with Vet-Stem Regenerative Cell Therapy
11. Cytos Biotechnology Ltd Reports Third Quarter 2013 Financial Results and Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... , June 20, 2017  Kibow Biotech Inc., ... to announce the issuance of a new patent covering ... hyperuricemia by the U.S. Patent and Trademark Office on ... winner of the Buzz of Bio award in 2014 ... akin to developing non-drug approaches to chronic disease. Renadylâ„¢, ...
(Date:6/20/2017)... ... June 20, 2017 , ... Do More with OHAUS , With ... a trusted supplier in the weighing industry, to extending its expertise across the entire ... reactions, immunoassays, hybridizations and more, allowing for its customers to 'Do More' ...
(Date:6/19/2017)... ... 19, 2017 , ... As Vice President, Product Services, Mr. ... implementation, support, and client process and SOP development. , Mr. Guinter brings a ... roles for service providers and top-tier pharmaceuticals, and as an independent consultant supported ...
(Date:6/19/2017)... (PRWEB) , ... June 19, 2017 , ... Tunnell ... for over 50 years. One of the biggest challenges faced by life sciences, biotech ... regulatory affairs services team is Kati Abraham , who is well known in ...
Breaking Biology Technology:
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
(Date:3/30/2017)... 2017 The research team of The Hong ... fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery and ... speed and accuracy for use in identification, crime investigation, immigration control, ... ... A research team led ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):